These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31774943)

  • 1. Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone.
    Gründer P; Augustin M; Paulzen M; Gründer G
    J Clin Psychiatry; 2019 Nov; 80(6):. PubMed ID: 31774943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.
    Paulzen M; Haen E; Stegmann B; Hiemke C; Gründer G; Lammertz SE; Schoretsanitis G
    Psychoneuroendocrinology; 2016 Nov; 73():9-15. PubMed ID: 27448523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism.
    Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Schizophr Res; 2017 Jul; 185():51-57. PubMed ID: 27993531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.
    Paulzen M; Haen E; Stegmann B; Unterecker S; Hiemke C; Gründer G; Schoretsanitis G
    Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):325-333. PubMed ID: 27695935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
    Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
    Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic patterns of risperidone-associated adverse drug reactions.
    Schoretsanitis G; Stegmann B; Hiemke C; Gründer G; Schruers KR; Walther S; Lammertz SE; Haen E; Paulzen M
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1091-8. PubMed ID: 27376639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
    Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
    J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.
    Taurines R; Fekete S; Preuss-Wiedenhoff A; Warnke A; Wewetzer C; Plener P; Burger R; Gerlach M; Romanos M; Egberts KM
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):689-701. PubMed ID: 35303169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
    Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
    J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
    Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
    Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
    Schoretsanitis G; Haen E; Gründer G; Stegmann B; Schruers KR; Hiemke C; Lammertz SE; Paulzen M
    J Clin Psychopharmacol; 2016 Dec; 36(6):554-561. PubMed ID: 27811552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
    Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
    Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
    Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Someya T
    J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.
    Chen PS; Yang YK; Su SF; Liao YC; Chang JW; Yeh TL
    Psychiatry Clin Neurosci; 2004 Apr; 58(2):168-72. PubMed ID: 15009822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics.
    Paulzen M; Schoretsanitis G; Stegmann B; Hiemke C; Gründer G; Schruers KRJ; Walther S; Lammertz SE; Haen E
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jun; 76():101-106. PubMed ID: 28302501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
    Schoretsanitis G; de Leon J; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):130-137. PubMed ID: 29153926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects.
    Maxwell RA; Sweet RA; Mulsant BH; Rosen J; Kirshner MA; Kastango KB; Pollock BG
    J Geriatr Psychiatry Neurol; 2002; 15(2):77-81. PubMed ID: 12083597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Corrected Serum Concentrations and Metabolite to Parent Compound Ratios of Venlafaxine and Risperidone from Childhood to Old Age.
    Fekete S; Scherf-Clavel M; Gerlach M; Romanos M; Kittel-Schneider S; Unterecker S; Egberts K
    Pharmacopsychiatry; 2021 May; 54(3):117-125. PubMed ID: 33291155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential changes in the plasma concentration of risperidone following intentional overdose.
    Nishikage H; Nakanishi T; Takamitsu Y; Yamamoto J
    Clin Neuropharmacol; 2002; 25(6):307-9. PubMed ID: 12469003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.